4 days ago
Comments Off on Who is next in big pharma’s merger spree?
(Reuters) – Consolidation in the U.S. healthcare industry, which has already witnessed a string of multi-billion dollar deals, is expected to remain a major theme for the rest of 2019. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder/File Photo Bristol-Myers Squibb’s $74 billion acquisition of Celgene